

---

# Clinical Pathways Reimagined: Harnessing Implementation Science, Clinical Decision Support, Artificial Intelligence, and Behavior Nudges for Smarter Clinical Impact

Leigh Anne Bakel MD MSc, John Chuo MD MS, Jack Stevens PhD,  
& Amy Tyler MD MSCS

# Disclosures

- Leigh Anne Bakel:

- Funding sources:

- Colorado Department of Health and Environment

- Jack Stevens:

- Stock ownership:

- Procter and Gamble; Colgate Palmolive

- Funding sources:

- National Institute of Health
    - Administration for Children and Families
    - Patient-Centered Outcomes Research Institute
    - Worthington Industries Foundation
    - Centers for Disease Control and Prevention

- Amy Tyler:

- Stock ownership:

- BioFire



# Introductions and Ice Breaker

- At your table
  - Name
  - Institution
  - Share 1 challenge to implementing clinical pathways at your institution

---

# Learning Goal

Equip participants with practical, ready-to-use tools to design and sustain effective clinical pathways that overcome real-world implementation barriers.



# Session Objectives



Explain what a Clinical Pathway is and articulate why it serves as an effective strategy for translating evidence into practice.



Describe how Implementation Science can enhance the success of Clinical Pathway development and implementation



Identify novel pathway implementation strategies—such as clinical decision support, artificial intelligence, and behavioral nudges—to facilitate the uptake of Clinical Pathways.



# Why Clinical Pathways to implement evidence?

---

# Clinical Practice Guidelines vs. Clinical Pathways



Evidence Based Practice (EBP) is the "What"

Ex: Clinical Practice Guidelines-Asthma SMART therapy



Clinical Pathways are the "How"

Ex: Asthma Clinical Pathway

# Guidelines



CLINICAL PRACTICE  
GUIDELINES  
WE CAN TRUST

INSTITUTE OF MEDICINE  
OF THE NATIONAL ACADEMIES

*“Statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.”*

Institute of Medicine. *Clinical Guidelines We Can Trust*.  
The National Academies Press; 2011

---

# Clinical Pathways

1

Structured  
multidisciplinary  
care plan

2

Used to  
translate  
guidelines  
or  
evidence  
into **local  
context**

3



Details  
steps in  
treatment  
or care

4

Aims to  
standardize  
care for a  
specific  
population  
or clinical  
problem

# Clinical pathways for secondary care and the effects on professional practice, patient outcomes, length of stay and hospital costs

✉ Thomas Rotter, Leigh D Kinsman, Agnès Alsius, Shannon D Scott, Adegboyega Lawal, Ulrich Ronellenfitsch, Christopher Plishka, Gary Groot, Phil Woods, Chloe Coulson, Leigh Anne Bakel, Kim Sears, Amanda Ross-White, Andreas Machotta, Timothy J Schultz *Authors' declarations of interest*

	Stand-alone clinical pathway c/w usual care			
	 Usual Care	 Stand-alone Clinical Pathway	Meta-Analysis (95% CI)	Participants & Quality of evidence
<b>Inhospital mortality</b>	<b>156</b> per 1,000 patients	<b>127</b> per 1,000 patients	OR 0.79 (0.53 to 1.20)	4,603 participants (7 RCTs) Quality of evidence <b>Low</b>
<b>Mortality</b> (up to 6 months)	<b>32</b> per 1,000 patients	<b>43</b> per 1,000 patients	OR 1.37 (0.72 to 2.60)	805 participants (3 RCTs) Quality of evidence <b>Low</b>
<b>Inhospital Complications</b> (rate of infections, pressure injuries, pain, uncontrolled bleeding)	<b>169</b> per 1,000 patients	<b>104</b> per 1,000 patients	★ OR 0.57 (0.41 to 0.80)	3,368 participants (11 RCTs) Quality of evidence <b>Moderate</b>
<b>Hospital Readmission</b> (up to 6 months)	<b>131</b> per 1,000 patients	<b>92</b> per 1,000 patients	OR 0.67 (0.44 to 1.03)	1,578 participants (9 RCTs) Quality of Evidence <b>Very low</b>
<b>Length of Hospital Stay</b> (from admission to discharge)	Not calculated due to absence of baseline data	<b>1.12</b> days lower	★ MD 1.12 days lower (1.6 lower to 0.65 lower)	5,201 participants (21 RCTs) Quality of evidence <b>Moderate</b>
<b>Hospital Costs and Charges</b>	Nine studies reported reductions in hospital costs and charges One study reported an increase in hospital costs		Results from 10 RCTs were too heterogeneous to combine in a meta-analysis	2,113 participants (10 RCTs) Quality of evidence <b>Very low</b>
<b>Adherence to recommended practice</b>	Six studies reported that clinical pathways increase adherence. One study reported no evidence of a difference.		Results from 3 comparable randomized studies were too heterogeneous to combine in a meta-analysis	2874 participants (7 studies) Quality of evidence <b>Low</b>

## Clinical pathways for secondary care and the effects on professional practice, patient outcomes, length of stay and hospital costs

✉ Thomas Rotter, Leigh D Kinsman, Agnès Alsius, Shannon D Scott, Adegboyega Lawal, Ulrich Ronellenfitsch, Christopher Plishka, Gary Groot, Phil Woods, Chloe Coulson, Leigh Anne Bakel, Kim Sears, Amanda Ross-White, Andreas Machotta, Timothy J Schultz Authors' declarations of interest

- Implementation Strategies
  - Limited by poor reporting
  - Need more studies

# Why Clinical Pathways?

## Interventions Aimed at Reducing Use of Low-Value Health Services: A Systematic Review

Medical Care Research and Review  
2017, Vol. 74(5) 507-550  
© The Author(s) 2016  
Reprints and permissions:  
sagepub.com/journalsPermissions.nav  
DOI: 10.1177/1077558716656970  
journals.sagepub.com/home/mcr  
SAGE

Carrie H. Colla<sup>1</sup>, Alexander J. Mainor<sup>1</sup>,  
Courtney Hargreaves<sup>1</sup>, Thomas Sequist<sup>2,3,4</sup>,  
and Nancy Morden<sup>1,5</sup>

Interventions




Figure 1. Overall effectiveness by category of intervention (N = 84).

# Why Clinical Pathways?






Figure 1. Overall effectiveness by category of intervention (N = 84).

# Session Objectives



Explain what a Clinical Pathway is and articulate why it serves as an effective strategy for translating evidence into practice.



Describe how Implementation Science can enhance the success of Clinical Pathway development and implementation



Identify novel pathway implementation strategies—such as clinical decision support, artificial intelligence, and behavioral nudges—to facilitate the uptake of Clinical Pathways.




# How Can Implementation Science Help with Clinical Pathways?





Change Process






# Implementation Science

- Definition
- The study of methods to promote the **integration** of research findings and evidence **into healthcare policy and practice**. – NIH
- Focus:
- Developing approaches to **close the gap** between what is known (research findings) and what is practiced (by clinicians).

---


# Implementation Science




“We built a pathway”





“The pathway changed care.”








# Barriers



---

# Implementation Science for Pathways






# Identify Barriers

# Implementation Science Frameworks

---

Understand how context/barriers affect a desired change




Consolidated Framework for  
Implementation Science (CFIR)

integrated - Promoting Action  
on Research Implementation in  
Health Services (i-PARIHS)


Practical Robust  
Implementation and  
Sustainability Model (PRISM)

# Practical, Robust Implementation and Sustainability Model (PRISM)




What organizational partners and patients think about the Evidence/Pathway


# Practical, Robust Implementation and Sustainability Model (PRISM)



# Practical, Robust Implementation and Sustainability Model (PRISM)




# Fishbone Diagram




# Merging the Fish Bone Diagram with PRISM Framework

## Practical, Robust Implementation and Sustainability Model 29



---

# Addressing the Barriers




---

# Barriers Inform Choice of Pathway Implementation Strategies

- There are no universally effective strategies
- More research needs to be done to understand which strategies are most effective for which barriers
- We rely on the “tried and true” methods (e.g., audits/feedback, education)

# Implementation Science for Pathways



# What do we need for strategy to work?

---

*What would overcome the barrier?*

*Why would it overcome the barrier?*

*How would it work?*



- What is feasible and impactful?
- **Theory about how strategies overcome barriers**
- **Process through which it may work**
- **Light Switch (Preconditions): Strategy works **only if present****
- Resources, Authority to change practice, Leadership support
- **Dimmer Switch (Moderators): Influence **how strongly a strategy works****
- Culture, Team engagement, Competing priorities



# Breakout 1

Using Implementation Science Frameworks to identify and address barriers influencing development and implementation of your Clinical Pathway

# Breakout 1: PRISM Cause-Effect Diagram



**Institution has lower adoption of guidelines compared to other similar institutions**

# Session Objectives



Explain what a Clinical Pathway is and articulate why it serves as an effective strategy for translating evidence into practice.



Describe how Implementation Science can enhance the success of Clinical Pathway development and implementation




Identify novel pathway implementation strategies—such as clinical decision support, artificial intelligence, and behavioral nudges—to facilitate the uptake of Clinical Pathways.



# Clinical Decision Support

## Logistical Barrier


# 6 Rights of Clinical Decision Support (CDS)



Right information



Right person



Right format



Right channel



Right time



Right purpose

---

# Asthma Pathway

- <https://agile.md/a/3zwxTmHnkEGA411E5rFR7bP1oZY9z44aqDfrdyJhmyTCXhcgxc>



# Artificial Intelligence

## Logistical Barrier

# KEY PRINCIPLES OF AI ENGAGEMENT



**YOU** REMAIN  
THE EXPERT  
AI IS A SUPER  
SMART  
ASSISTANT WHO  
THINKS IT  
KNOWS  
EVERYTHING



WORK  
**SMARTER,**  
**NOT**  
**HARDER**  
(MORE  
EFFICENCY)



**GARBAGE**  
IN, GARBAGE  
OUT (WHO IS  
TEACHING  
AI?)



**CHECK** AND  
DOUBLE CHECK  
(AI IS VERY  
CONVINCING)




BEWARE OF PUBLIC GPT  
**DO NOT USE**  
IDENTIFIERS  
(CHECK WITH YOUR  
INSTITUTION)

---

# SYNERGY

AI Agent to  
improve Clinical  
Care




# CASE Example


## Neonatal Resuscitation Program, 9<sup>th</sup> Edition

- We created a Job Aid to highlight the new changes
- PDSA #1: disseminated via email to 105 providers
  - Observed poor practice uptake (persistent 8<sup>th</sup> edition practice)
- PDSA #2: “Contest game”
  - Divide provider into 4 groups
  - Weekly 3 questions X 6 weeks
  - Winning team goes to an Alaska cruise vacation.

# Swimlane of PDSA#2 – Contest game



# Exercise - AI Agent Improvement PDSA Ramp



# Swimlane of Collaboration between SME and Engineer to create AI Agent NRP Question Generator

Subject  
Matter  
Expert

Creates resource  
of truth

Software  
Engineer

Builds NRP AI  
Assistant

No, Updates AI instruction with improvements

NRP  
Instructor

Prompts to  
create  
questions

Need to  
Improve  
Prompt??

NRP AI  
Assistant

Creates and  
displays questions

Yes

# Baseline data from sending out human made questions

(to be compared with AI generated questions in upcoming comparative study)

Date Sent	Question	Preferred Answer	# of respondents	% correct
1/7/2026	A. 8.1 Deferred Cord Clamping You are reviewing the NRP 9th edition updates on deferred cord clamping (DCC) with your delivery team. Which statement is correct?	If the infant is vigorous, DCC should be performed for at least 60 seconds	80	96%
1/21/2026	8.2 NRP 9th DR PIP According to the NRP 9th edition, when preparing for a 28-week gestational age delivery, what should the initial PIP be set at?	20-25 cm of H2O	83	83%
2/4/2026	A. 8.3 NRP 9th DR FiO2 According to the NRP 9th edition, when preparing for a 33-week gestational age delivery, what should the initial FiO2 be set at?	21%-30%	81	98%

# KEY PRINCIPLES OF AI ENGAGEMENT



**YOU** REMAIN  
THE EXPERT  
AI IS A SUPPER  
SMART  
ASSISTANT



**WORK  
SMARTER,  
NOT  
HARDER**



**GARBAGE  
IN, GARBAGE  
OUT**



**CHECK AND  
DOUBLE CHECK**



BEWARE OF PUBLIC GPT  
**DO NOT USE  
IDENTIFIERS**  
CHECK WITH YOUR  
INSTITUTION



# Behavioral Economics

Behavioral Barrier

---

## Patel, Volpp & Asch (January 2018 Perspective; New England Journal of Medicine) “Nudge Units”

- “The final common pathway for the application of nearly every advance in medicine is human behavior. No matter how effective a drug, how protective a vaccine, or how targeted a therapy may be, a clinician usually has to prescribe it, and a patient accept and use it as directed, for it to improve health” (pg. 214).
- *--Leaders of the USA’s first health care system “Nudge Unit” (established 2016 at UPenn Med)*



# What is Behavioral Economics (BE)?

Interdisciplinary field featuring insights from psychology and economics

- Common focus of BE: financial well-being
- **You** may have novel applications of BE!

---

# Two Branches of Behavioral Economics

Financial  
Incentives

- Optimal design of rewards and penalties

Messages;  
Choice  
Architecture

- Optimal presentation of opportunities  
“Nudges” (Thaler and Sunstein, 2021)

# Example of a Nudge – Global Positioning System (GPS)

- Brief and firm instructions
- Helpful information (most of the time)
- Optional advice
- Respectful tone
- (partially based on Thaler and Sunstein, *Nudge*, 2021)



---

# Empirical Support for Nudges

Last BS, Bутtenheim AM, Timon CE, et al. Systematic review of clinician-directed nudges in healthcare contexts. *BMJ Open* **2021**; 11:e048801.

Wang SY, Groene O. The effectiveness of behavioral economics-informed interventions on physician behavioral change: A systematic literature review. *PLoS ONE* **2020**; 15(6): e0234149.

Talat U, Schmidtke KA, Khanal S, et al. A systematic review of nudge interventions to optimize medication prescribing. *Frontiers in Pharmacology* **2022**; 13: Article 798916

**Tang MY, Rhodes S, Powell R, et al. How effective are social norms interventions in changing the clinical behaviours of healthcare workers? A systematic review and meta-analysis. *Implementation Science* 2021; 16(1): 8.**

---

# Example of a Nudge: Highlighting Social Norms – “Peer Comparisons”

- Social influences, not just biological facts, can encourage people to behave more optimally.
- The Hotel Towel Study (Goldstein et al., 2008)



# Possible Mechanisms of Action for Peer Comparisons

- **Social proof:** “This behavior must be worthwhile and acceptable if others display it.” (Deutsch M & Gerard HB., 1955 *J Abnorm Soc Psychol*)
- **Self-efficacy:** “I can display this particular behavior too.” (Stok FM et al., 2014; *Appl Psychol Health Well Being*)
- **Superiority biases:** “I am as good (if not better) than others.” (Hoorens V., 1993; *Eur Rev Soc Psychol.*)

---

# Empirical Studies of Peer Comparisons to Nudge Medication Prescribers

## 1. Emergency department opioid prescribing

Andereck et al. *The Joint Commission Journal on Quality and Patient Safety*, 2019.

## 2. Primary care antipsychotic prescribing

Sacarny et al. *JAMA Psychiatry*, 2018.

## 3. Primary care antibiotic prescribing

Meeker et al. *JAMA*, 2016.


---

# Highlighting Those Exhibiting the Desired Behavior



---

# Avoid Highlighting The Many People Exhibiting the Opposite Behavior –The “Big Mistake” from Dr. Robert Cialdini



---

# Descriptive norms probably work best when...

- people are unaware of the desired behavior exhibited by many *similar* individuals. Peers matter!
- an increasingly popular trend is highlighted (Mortensen et al., 2017; *Social Psychological and Personality Science*).
- “Many” is fine; “Most” is not required.

# Don't Forget Those Who Perform Well

**Different from just “personalized feedback”**

	Month 1	Month 2
Neighbor 1	\$200	\$190
Neighbor 2	\$100	\$110
<hr/>		
TOTAL:	\$300	\$300

--based on Schultz et al. (2007) study on energy conservation

# Peer Comparisons

	Month 1	Month 2
Neighbor 1	\$200	\$190
Neighbor 2	\$100☺	\$100
<hr/>		
TOTAL:	\$300	\$290

**“You are a top performer”** (Meeker et al., *JAMA*, 2016)

---

# Long-Term Benefits of Peer Comparisons

- Can lead to enduring changes in clinical practice

Linder JA, Meeker D, Friedberg MW, Persell SD, Goldstein NJ, Doctor JN. Effects of behavioral interventions on inappropriate antibiotic prescribing in primary care 12 months after stopping interventions. *JAMA*. 2017;318:1391–2.

# Checklist for Utilizing Social Norms

## •Do:

- Highlight similar clinicians using the clinical pathway
- Highlight an increasingly popular trend
- Highlight peer comparisons to those who are ambivalent about the pathway or are busy/distracted but interested in the pathway

## •Don't:


- Forget to praise high utilizers of the pathway
- Highlight that many clinicians fail to utilize the pathway
- Bother to highlight norms to those clinicians who are “rebellious” or who are strongly opposed to the pathway

---

# Whole Wheat Bread



# Session Objectives



Explain what a Clinical Pathway is and articulate why it serves as an effective strategy for translating evidence into practice.



Describe how Implementation Science can enhance the success of Clinical Pathway development and implementation



Identify novel pathway implementation strategies—such as clinical decision support, artificial intelligence, and behavioral nudges—to facilitate the uptake of Clinical Pathways.

Please fill out the  
evaluation

[Leighanne.bakel@childrenscolorado.org](mailto:Leighanne.bakel@childrenscolorado.org)

[Chuoj@chop.edu](mailto:Chuoj@chop.edu)

[Jack.Stevens@Nationwidechildrens.org](mailto:Jack.Stevens@Nationwidechildrens.org)

[Amy.Tyler@Nationwidechildrens.org](mailto:Amy.Tyler@Nationwidechildrens.org)

Thank you!!!





# Book Chapter Reference

Stevens J (2020). Accountable justifications and peer comparisons as behavioral economic nudges to improve clinical practice. In R. Shah & S. Godambe (Eds.) Patient Safety and Quality Improvement in Healthcare: A Case-Based Approach. New York: Springer.



# Extra Slides